Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy.
about
Review: Multiple system atrophy: emerging targets for interventional therapiesMultiple system atrophy: a clinical and neuropathological perspectiveAnimal models of multiple system atrophyAnimal modeling an oligodendrogliopathy--multiple system atrophyModulating self-assembly of amyloidogenic proteins as a therapeutic approach for neurodegenerative diseases: strategies and mechanismsEfficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial.The Cleavage Effect of Mesenchymal Stem Cell and Its Derived Matrix Metalloproteinase-2 on Extracellular α-Synuclein Aggregates in Parkinsonian ModelsTowards translational therapies for multiple system atrophyMitochondrial inhibitor 3-nitroproprionic acid enhances oxidative modification of alpha-synuclein in a transgenic mouse model of multiple system atrophyExpression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model tMultiple system atrophy: current and future approaches to managementTherapeutic advances in multiple system atrophy and progressive supranuclear palsy.Preserved functional autonomic phenotype in adult mice overexpressing moderate levels of human alpha-synuclein in oligodendrocytes.Novel therapeutic approaches in multiple system atrophyModels of multiple system atrophyOptimizing clinical trial design for multiple system atrophy: lessons from the rifampicin study.The natural history of multiple system atrophy: a prospective European cohort studyNew horizons in the pathogenesis, assessment and management of movement disorders.The role of glia in α-synucleinopathies.Multiple System Atrophy - State of the Art.Alpha-synuclein deficient mice are resistant to toxin-induced multiple system atrophy.Rifampicin is a candidate preventive medicine against amyloid-β and tau oligomers.
P2860
Q26770919-712D093C-34F2-4212-BD16-F973B53D7F96Q26829838-5CC440A6-490D-4239-AE42-988B482CDE24Q27015535-33D72C12-8CB8-402A-ACF7-3239FB887A16Q28074659-A6351E85-E08B-4F20-B774-E4D4BCB116E6Q28259424-326FA1FE-0686-410C-834C-1351969C6AB0Q33649211-73C99C88-4577-4C15-A907-2375435F4C80Q33722313-EA2FB71F-3146-4197-B171-C2957160B6CBQ33797532-486D1AD0-BDA0-48F8-9C99-D88D2797D5B7Q33914242-672CFD79-F218-4231-BF59-94297FE5A59EQ34321875-525FBE81-F395-4F00-8F23-DFB00D11E4DBQ34409502-1DC0AC46-0299-4C00-AC79-F2B15CD05611Q34487619-6FDDB4CB-ED46-4265-B2E7-667954D993C0Q34631931-AD989FAD-D5B2-4DBD-AECC-588ED6B105E5Q34696470-B42CF2E1-7EA9-4410-B4DF-257FEEAD430FQ36513407-2B0ACF6C-A5D8-4D04-91EB-4DBA680D438DQ36607225-C0BDE879-38A2-430C-B4CF-C6E4204D18BAQ36637012-B502F94A-D825-437C-96D3-21D046AEDBC6Q38036239-69921E20-7A48-4759-94B6-CC096824EB51Q38039880-C28A1C7C-1569-49F8-A405-9E5199ADEF5AQ39220912-4498E2AD-5D02-4B30-9439-CE30660BF5E3Q42014854-53F85E47-92F2-48C9-A0B6-3D73E03D0BA7Q50525085-6F9FC6D5-6DBD-4F0A-82C2-86B8749734CF
P2860
Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Rifampicin reduces alpha-synuc ...... el of multiple system atrophy.
@en
type
label
Rifampicin reduces alpha-synuc ...... el of multiple system atrophy.
@en
prefLabel
Rifampicin reduces alpha-synuc ...... el of multiple system atrophy.
@en
P2093
P2860
P50
P1433
P1476
Rifampicin reduces alpha-synuc ...... el of multiple system atrophy.
@en
P2093
Anthony Adame
Christina Patrick
Clifford Shults
Michael Mante
Monica Thukral
P2860
P304
P356
10.1097/WNR.0B013E32830B3661
P577
2008-08-01T00:00:00Z